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Background: Angelman syndrome (AS) is a severe neurodevelopmental disorder lacking effective therapies. AS
is caused by mutations in ubiquitin protein ligase E3A (UBE3A), which is genomically imprinted such that only
the maternally inherited copy is expressed in neurons. We previously demonstrated that topoisomerase I (Top1)
inhibitors could successfully reactivate the dormant paternal allele of Ube3a in neurons of a mouse model of AS.
We also previously showed that one such Top1 inhibitor, topotecan, could unsilence paternal UBE3A in induced
pluripotent stem cell-derived neurons from individuals with AS. Although topotecan has been well-studied and
is FDA-approved for cancer therapy, its limited CNS bioavailability will likely restrict the therapeutic use of
topotecan in AS. The goal of this study was to identify additional Top1 inhibitors with similar efficacy as
topotecan, with the expectation that these could be tested in the future for safety and CNS bioavailability
to assess their potential as AS therapeutics.
Methods: We tested 13 indenoisoquinoline-derived Top1 inhibitors to identify compounds that unsilence the paternal
allele of Ube3a in mouse neurons. Primary cortical neurons were isolated from embryonic day 14.5 (E14.5) mice with a
Ube3a-YFP fluorescent tag on the paternal allele (Ube3am+/pYFP mice) or mice that lack the maternal Ube3a allele and
hence model AS (Ube3am−/p+ mice). Neurons were cultured for 7 days, treated with drug for 72 h, and examined for
paternal UBE3A protein expression by Western blot or fluorescence immunostaining. Dose responses of the compounds
were determined across a log range of drug treatments, and cytotoxicity was tested using a luciferase-based assay.
Results: All 13 indenoisoquinoline-derived Top1 inhibitors unsilenced paternal Ube3a. Several compounds exhibited
favorable paternal Ube3a unsilencing properties, similar to topotecan, and of these, indotecan (LMP400) was the most
effective based on estimated Emax (maximum response of unsilencing paternal Ube3a) and EC50 (half maximal effective
concentration).
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Conclusions: We provide pharmacological profiles of indenoisoquinoline-derived Top1 inhibitors as paternal Ube3a
unsilencers. All 13 tested compounds were effective at unsilencing paternal Ube3a, although with variable efficacy and
potency. Indotecan (LMP400) demonstrated a better pharmacological profile of Ube3a unsilencing compared to our
previous lead compound, topotecan. Taken together, indotecan and its structural analogues are potential AS
therapeutics whose translational potential in AS treatment should be further assessed.
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IndotecanBackground
Angelman syndrome (AS) is a severe neurodevelopmental
disorder characterized by developmental delay, intellectual
disability, speech impairment, seizures, and ataxia [1–5].
AS has a prevalence of 1:15,000 [6, 7], and these individuals
need care across their full lifespan, yet no cure currently ex-
ists. Thus, it is of great importance to develop treatments
for AS. AS is caused by mutation of the ubiquitin protein
ligase E3A (UBE3A) gene, which is genomically imprinted.
Only the maternally inherited copy is expressed in neurons
[8], whereas UBE3A is biallelically expressed in most other
tissues. This neuron-specific imprinting provides insight
into why deletions or mutations in the maternal copy of
UBE3A primarily impact brain function and cause AS.
However, the paternal UBE3A allele is intact, as demon-
strated by biallelic expression in other tissues, raising the
possibility that AS could be treated by unsilencing the
dormant paternal UBE3A allele in neurons.
This led us to try pharmacological approaches to identify
small molecules capable of unsilencing the dormant copy
of UBE3A. In a previous study, we developed a high-
content assay to identify small molecules that could unsi-
lence paternal Ube3a in mouse primary neurons. In that
screen, we used knock-in mice carrying a yellow fluorescent
protein (YFP)-tagged Ube3a reporter, allowing us to
visualize maternal- or paternal-specific expression of
Ube3a-YFP in cultured neurons. As expected, Ube3a-YFP
was expressed in cultured neurons when inherited mater-
nally but was not expressed (silenced) when inherited pa-
ternally. We found that topoisomerase I (Top1) inhibitors
(e.g., topotecan) could effectively unsilence paternal Ube3a
in mice [9], raising the possibility that topotecan or similar
compounds [10] could become treatments for AS. The
translational potential was supported by evidence that topo-
tecan treatment biochemically rescued the function of
UBE3A, unsilenced Ube3a in vivo in mice, and unsilenced
paternal UBE3A in induced pluripotent stem cell-derived
neurons of AS patients [11].
Topotecan is FDA-approved for the treatment of cancer
and is well tolerated in adult and pediatric cancer patients
[12–15]. It is also used to treat brain tumors [16, 17].
Topotecan crosses the BBB more readily than many topo-
isomerase inhibitors [18]. However, active pumps extrudetopotecan from the brain, which limits its functional CNS
bioavailability [19, 20]. Moreover, topotecan can produce
some toxicities [21, 22]. These limitations prompted us to
search for novel Top1 inhibitors with better CNS bioavail-
ability and improved safety profiles.
Indenoisoquinoline-derived Top1 inhibitors offer a prom-
ising class of compounds for paternal Ube3a unsilencing as
many of these compounds produce particularly stable Top1
cleavage complexes [23–25], which we have shown are crit-
ical for producing paternal Ube3a unsilencing [26]. Over
300 indenoisoquinoline derivatives have been tested, some
of which are very potent Top1 poisons and show antitumor
activity in mouse models [10, 27–31]. These Top1
inhibitors work by blocking the enzymatic activity of
Top1 by stabilizing cleavage complexes, which are
compound-bound intermediates of Top1-DNA [10,
23–25, 32]. More importantly, when compared to
topotecan, indenoisoquinoline-derived Top1 inhibitors
demonstrate improved characteristics such as greater
chemical stability of these cleavage complexes. In
addition, they target a unique DNA sequence for
cleavage (indenoisoquinolines --G↓C-- vs. topotecan
--T↓G--) [23–25, 32].
The goal of this study was to establish indenoisoquino-
line derivatives that could effectively unsilence paternal
Ube3a, with the expectation that some of these com-
pounds might prove to be safe and have favorable CNS
bioavailability. All of the tested compounds showed a
capacity to unsilence the paternal Ube3a allele, with sev-
eral of the compounds exhibiting unsilencing efficacy
similar to topotecan. Excitingly, two of the tested inde-
noisoquinoline derivatives, indotecan (LMP400) and
indimitecan (LMP776), are already in clinical trials [33,
34]. The results of our study suggest additional Top1 in-
hibitors that should be advanced for AS preclinical test-
ing of safety and CNS efficacy.
Methods
Animals
All animal experiments were handled with an Institu-
tional Animal Care and Use Committee (IACUC) proto-
col approved by the University of North Carolina School
of Medicine. AS model mice [35] (Ube3am−/p+) were
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males. Paternal YFP-tagged mice [36] (Ube3am+/pYFP)
were generated by crossing heterozygote Ube3a-YFP
males with wildtype females. Mice were housed at
12 h:12 h LD and given ad libitum access to water and
food. Both male and female mice (embryos) were used
in all studies.Chemistry
Topotecan was purchased from Cayman Chemicals. Indo-
tecan (LMP400) and indimitecan (LMP776) were obtained
from the Developmental Therapeutics Program (DTP)
branch, National Cancer Institute. Eleven structural ana-
logues of indotecan and indimitecan, all indenoisoquinoline
derivatives, were provided by Dr. Mark Cushman at Purdue
University. Syntheses of 12 indenoisoquinolines have been
previously described: indotecan (LMP400) and indimitecan
(LMP776) [33], DB-III-17, DB-IV-26, DB-IV-50, DB-IV-56,
DB-IV-58, DB-V-37, DB-V-41, DB-V-46, and DB-V-47 [37],
and MJ-II-66A [30]. MNR-IV-64 was synthesized by the
procedure reported for the corresponding N-4′-hydroxybu-
tyl analogue [30]. These compounds were selected because
they have a wide range of cytotoxicities in cancer cell cul-
ture while maintaining some degree of Top1 inhibitoryA
B
Fig. 1 Like the camptothecin-derived topotecan, indenoisoquinoline derivative
of nuclei (Hoeschst stain) and paternal UBE3A-YFP in drug-treated cultured mou
Ube3a-YFP was unsilenced by the indicated drugs [topotecan (0.3 μM), indoteca
not by DMSO vehicle control (scale bar = 100 μm). DB-IV-58 and DB-V-37 are st
neurons expressing unsilenced paternal UBE3A-YFP (n= 4 wells in 384-well platactivity. All compounds were stored at − 20 °C before being
reconstituted in dimethyl sulfoxide (DMSO) prior to use.Cell culture and drug treatment
Primary cortical neurons were isolated and cultured using
previously described protocols [9]. Briefly, we isolated cor-
tical neurons from embryos (E14.5) carrying paternal
Ube3a-YFP (Ube3am+/pYFP) or maternal deletion of Ube3a
(Ube3am−/p+). Isolated cortical neurons were plated onto
384-well plates (~ 25,000 cells/well) for high-content im-
aging and onto 6-well plates (~ 1,000,000 cells/well) for
Western blot analysis. Cultured neurons were initially incu-
bated for 7 days, replacing culture medium every 3–4 days.
Drugs were freshly prepared in DMSO as a 10-mM stock,
unless further dilution in DMSO was necessary. On day 7
(DIV 7), the indicated compounds (topotecan, indotecan,
indimitecan, DB-IV-58, and DB-V-37 in Figs. 1, 2, and 3)
were directly added at 0.3 μM (final concentration in cul-
ture medium) to the neurons for 72 h to allow time for
unsilencing of paternal Ube3a or Ube3a-YFP. For dose de-
pendence and cytotoxicity tests (Fig. 4 and Additional file 1),
we used half-log molar drug concentrations, 1 × 10−10, 3 ×
10−10, 1 × 10−9, 3 × 10−9, 1 × 10−8, 3 × 10−8, 1 × 10−7, 3 ×
10−7, 1 × 10−6, 3 × 10−6, 1 × 10−5, and 3 × 10−5 M.s can unsilence paternal Ube3a-YFP in vitro. a Immunofluorescence images
se cortical neurons and chemical structures of the compounds. Paternal
n (0.3 μM), indimitecan (0.3 μM), DB-IV-58 (0.3 μM), or DB-V-37 (0.3 μM)] but
ructural analogues of indotecan and indimitecan. b Quantitative analysis of
e/group, *p < 0.05)
A B
Fig. 2 Western blot analysis demonstrating the capacity of indenoisoquinoline derivatives to increase paternal UBE3A-YFP at the protein level in cultured
neurons from Ube3am+/pYFP mice. a Immunoblot and quantification of UBE3A-YFP levels normalized to actin in cultured neurons from wildtype (WT) or
Ube3am+/pYFP mice treated with DMSO (0.1% vehicle control), topotecan (0.3 μM), indotecan (0.3 μM), or indimitecan (0.3 μM) (n= 3/group, *p< 0.05). b
Immunoblots and quantification of UBE3A-YFP levels normalized to actin in cultured neurons from wildtype (WT) or Ube3am+/pYFP mice treated with DMSO
(0.1% vehicle control), topotecan (0.3 μM), DB-IV-58 (0.3 μM), or DB-V-37 (0.3 μM) (n= 3/group, *p< 0.05)
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We followed the protocols for fluorescent immunostain-
ing and high-content imaging of cortical neurons as pre-
viously described [9, 38]. Briefly, 72 h after drug
treatment, the cells were fixed with 4% paraformalde-
hyde at room temperature for 15 min. After rinsing with
phosphate-buffered saline (PBS) three times, the cells
were permeabilized with 1% Triton-X 100 in PBS,
followed by blocking with 5% NGS and 0.1% Triton-X
100 in PBS at room temperature for 30 min. After block-
ing, the cells were incubated with primary antibody,
rabbit anti-GFP (1:1000, Novus Biologicals), at 4 °C over-
night. The cells were then briefly rinsed with PBS
followed by incubation with secondary antibody, goat
anti-rabbit Alexa Fluor 488 (1:200, Thermo Fisher/Invi-
trogen), at room temperature. One hour after secondary
antibody incubation, the cells were rinsed with PBS and
fluorescent images were acquired using a BD Pathway
855 bioimager. The acquired images were processed by
CellProfiler [39] to count the number of positive cells
and measure fluorescent intensity (Additional file 2). To
determine the percentage of neurons expressing paternal
Ube3a-YFP, we counted the total number of cells
(Hoechst) and YFP-positive cells, and the number ofYFP-positive cells was divided by the total number of
cells. Fluorescence intensity was measured in neurons
expressing unsilenced paternal Ube3a-YFP and normal-
ized to vehicle control.
Cytotoxicity test
Toxicity of the compounds was tested in cultured cortical
neurons in vitro. Using Cyto Tox-Glo assay (Promega), we
followed the manufacturer’s protocol to measure lumines-
cence proportional to the number of dead vs. live cells.
Briefly, 72 h after drug treatment, we directly added
AAF-Glo substrates into the drug-treated (or 0.1% DMSO
vehicle-treated) neurons and incubated them at room
temperature for 15 min. We then measured luminescence
produced by dead-cell protease activity.
Western blot analysis
We followed the same procedures of Western blot ana-
lysis as previously described [9, 38]. In brief, 72 h after
drug treatment, we collected the cultured neurons from
6-well plates and extracted total protein with protein ex-
traction buffer. Bradford assay was performed to meas-
ure protein concentration, and 30 μg of total protein
was loaded for Bis-polyacrylamide gel electrophoresis
Fig. 3 Indenoisoquinoline derivatives unsilence paternal Ube3a in AS
model mice (Ube3am−/p+). Immunoblot and quantification of UBE3A
levels normalized to actin in cultured neurons from wildtype (WT) or
Ube3am−p+ mice treated with DMSO (0.1% vehicle control), topotecan
(0.3 μM), indotecan (0.3 μM), indimitecan (0.3 μM), DB-IV-58 (0.3 μM), or
DB-V-37 (0.3 μM) (n = 3/group, *p < 0.05)
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nitrocellulose membrane (0.45 μm, Bio-Rad). The mem-
branes were blocked with 5% non-fat milk in TBS-T at
room temperature for 30 min followed by overnight 4 °C
incubation with primary antibodies (rabbit anti-GFP,
1:1000, Novus Biologicals; rabbit anti-Ube3a, 1:1000, Bethyl
Lab; mouse anti-actin; 1:5000, Sigma). The next day, the
membranes were rinsed with TBS-T three times and incu-
bated with HPR-conjugated secondary antibodies for 1 h at
room temperature (goat anti-rabbit, 1:1000, Vector Lab or
goat anti-mouse, 1:1000, Vector Lab). Following secondary
antibody incubation, the membranes were rinsed with
TBS-T at room temperature for 1 h (4–5 times) and ECL
substrates (Bio-Rad) were used to visualize immunostaining
using an Amersham Imager 600 (AI600, GE Life Sciences).
Statistical analysis
One-way ANOVA was performed to determine signifi-
cant differences in unsilencing paternal Ube3a-YFP or
Ube3a, followed by Dunnett’s multiple comparison test.Two-way ANOVA was performed to determine changes
in EC50, Emax, and LC50 (Table 1), with comparisons to
topotecan made using a Bonferroni correction for mul-
tiple comparisons.
Results
Indenoisoquinoline-derived topoisomerase I inhibitors
effectively unsilence paternal Ube3a
The goal of this study was to identify novel Top1
inhibitors as potential AS therapeutics. We chose to focus
on the compounds indotecan (LMP400), indimitecan
(LMP776), and their analogues because indotecan and
indimitecan recently completed phase I clinical trial test-
ing at the National Institutes of Health (ClinicalTrials.gov
ID: NCT01051635). Moreover, indotecan exhibits favor-
able CNS penetration [40]. Thus, these drugs have already
undergone a certain degree of preclinical safety testing,
which could expedite clinical development if warranted.
As we anticipated, paternal Ube3a-YFP was not expressed
at appreciable levels in cultured neurons in the presence of
0.1% DMSO (vehicle control). On the other hand, topote-
can (positive control) unsilenced paternal Ube3a-YFP as
previously reported [9] (Fig. 1a). Four indenoisoquinoline-
derived compounds (indotecan, indimitecan, DB-IV-58,
and DB-V-37) also successfully demonstrated unsilencing
of paternal Ube3a-YFP in our reporter mouse (Fig. 1a). We
quantified the number of Hoechst-positive cells expressing
paternal Ube3a-YFP above a defined threshold and found
that few (0.21 ± 0.17%) DMSO-treated neurons expressed
Ube3a-YFP above threshold (Fig. 1b). In contrast, a signifi-
cant (p < 0.05) number of neurons expressed paternal
Ube3a-YFP when cultures were treated with topotecan
(33.0 ± 2.56%), indotecan (37.1 ± 5.19%), indimitecan (23.9
± 1.72%), DB-IV-58 (17.7 ± 3.87%), or DB-V-37 (14.1 ±
3.55%) (Fig. 1b). The number of cells expressing paternal
Ube3a-YFP was similar between indotecan- and topotecan-
treated neurons at a dose of 0.3 μM. At this same concen-
tration (0.3 μM), fewer neurons treated with indimitecan,
DB-IV-58, or DB-V-37 expressed paternal Ube3a-YFP com-
pared to topotecan-treated neurons (p < 0.05 compared to
topotecan-treated neurons).
To validate the paternal Ube3a-YFP unsilencing and
definitively rule out the possibility of fluorescence arti-
facts (e.g., intrinsic fluorescence in compounds), we per-
formed Western blot analysis using primary cultured
cortical neurons. No UBE3A-YFP protein was expressed
in wildtype neurons (negative control), whereas paternal
UBE3A-YFP was marginally detectable in DMSO-treated
cells from Ube3am+/pYFP mice, possibly due to contamin-
ation from glial cells that express Ube3a biallelically or
to very modest expression of paternal Ube3a expressed
during early stages of development. Topotecan, indotecan,
indimitecan, DB-IV-58, and DB-V-37 treatments led to pa-
ternal UBE3A-YFP protein production (Fig. 2). Normalized
A B
Fig. 4 Pharmacological properties of four indenoisoquinoline derivatives in unsilencing paternal Ube3a-YFP in vitro. a Dose dependence of four
indenoisoquinoline derivatives and topotecan in unsilencing of paternal UBE3A-YFP (n = 4/group). Estimated potencies and efficacies of the drugs
are summarized in Table 1. b Dose-dependent cytotoxicities of four indenoisoquinoline derivatives and topotecan (n = 4/group). Estimated LC50
values are summarized in Table 1
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in all five tested drugs (bottom panels in Fig. 2a, b).
Although unlikely, we wanted to rule out the possi-
bility that the unsilencing was an artifact of the
Ube3a-YFP knock-in. Thus, we tested the drug effects
in AS model mice that lack the maternal Ube3a allele
(Ube3am−/p+ mice) (Fig. 3). There was little paternal UBE3A
protein in DMSO-treated Ube3am−/p+ neurons compared
to Ube3am+/p+ (wildtype) neurons. Topotecan, indotecan,
indimitecan, DB-IV-58, and DB-V-37 treatments result in a
high level of paternal UBE3A protein compared to
DMSO-treated neurons. These data confirm the ability of
the tested indenoisoquinolines to unsilence paternal Ube3a.
Pharmacological profiling of indenoisoquinoline Top1
inhibitors in cultured cortical neurons in vitro
Once we confirmed the unsilencing effects, we performed
pharmacological profiling of indotecan, indimitecan, andTable 1 Summary of efficacies and potencies of topotecan and inde
Compound EC50 [M]
Topotecan 3.04E−08 (± 3.40E−09)
Indotecan 2.56E−08 (± 1.05E−09)*
Indimitecan 7.47E−09 (± 7.49E−10)*
DB-IV-58 3.10E−08 (± 9.75E−09)
DB-V-37 2.99E−08 (± 8.29E−09)
EC50, Emax, and LC50 are estimated from data presented in Fig. 4. Significance was t
comparisons to determine significant differences (*p < 0.05) from topotecan-treatedtheir analogues for structure-activity relationships in order
to identify more effective unsilencers. We performed
dose-response experiments for all tested compounds (Fig. 4a
and Additional file 1). These experiments identified indote-
can as the most efficacious of all of drugs tested, with the
potency (EC50) of indotecan being significantly better than
topotecan (Table 1; *p < 0.05). This suggests indotecan may
have potential as a possible AS therapeutic. Indimitecan is
less likely as a candidate therapeutic, because although it
exhibited good potency in a nanomolar range and had simi-
lar efficacy as topotecan (Fig. 4a and Table 1, *p < 0.05), it
likely has a low therapeutic index (discussed below). We
also examined 11 structural analogues. Among 11 com-
pounds, we found two of them, DB-IV-58 and DB-V-37,
with similar efficacy and potency to topotecan (Fig. 4a and
Table 1). However, they were less effective than indotecan.
Indenoisoquinoline derivatives were primarily designed
to inhibit cancer cell growth. Because our goal is tonoisoquinoline derivatives
Emax LC50 [M]
1.51 (± 0.11) 2.30E−06 (± 2.01E−08)
1.78 (± 0.13)* 2.01E−06 (± 1.59E−07)
1.47 (± 0.10) 7.89E−07 (± 3.43E−08)*
1.45 (± 0.12) 2.01E−06 (± 1.09E−07)
1.48 (± 0.08) 2.02E−06 (± 1.02E−07)
ested by two-way ANOVA, followed by a Bonferroni correction for multiple
neurons
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necessary to test whether the compounds would be
deleterious in neuronal cells. Toxicity testing of four
indenoisoquinoline-derived compounds (indotecan,
DB-IV-58, DB-V-37, and indimitecan) in the cultured
neurons revealed that the cytotoxicity of the first
three drugs (indotecan, DB-IV-58, and DB-V-37) was
similar to that of topotecan. On the other hand,
indimitecan exhibited toxicity at a significantly lower
concentration than topotecan (Fig. 4b and Table 1,
*p < 0.05), suggesting that it might have a low thera-
peutic index. Lastly, we also tested dose dependency
of nine additional analogues (Additional file 1 and
Additional file 3: Table S1). All nine compounds
could unsilence paternal Ube3a-YFP to a certain degree.
However, their effectiveness did not exceed that of
indotecan. Three compounds (DB-IV-50, DB-IV-56, and
MNR-IV-64) share similar pharmacological profiles, as their
efficacy and potency were similar. However, their effective-
ness of unsilencing paternal Ube3a-YFP was less than our
lead compounds. Six compounds (DB-III-17, DB-IV-26,
DB-V-41, DB-V-46, DB-V-47, and MJ-II-66A) unsilenced
paternal Ube3a-YFP to a certain degree; however, they
showed a very limited range of doses that produce
Ube3a-YFP unsilencing before showing toxicities (e.g., an
unfavorable therapeutic index). Because of the limited dose
ranges, their EC50 values were not clearly determined (Add-
itional file 3: Table S1). These data together suggest that,
compared to topotecan, indotecan has a higher potency
and efficacy, but similar toxicity profile, in its ability to unsi-
lence the dormant paternal Ube3a allele in neurons.
Discussion
The goal of this study was to explore indenoisoquinoline
derivatives as possible AS therapeutics by characterizing
their effects on Ube3a unsilencing in mouse cortical
neurons in vitro. Here, we identify indotecan (LMP400)
as a potential AS therapeutic agent that warrants further
examination in vivo for CNS bioavailability and safety.
The unique expression of UBE3A governed by genomic
imprinting provides a therapeutic opportunity for AS by
reactivating the paternal UBE3A allele [8, 9, 11]. Our re-
search team previously reported that topoisomerase I in-
hibitors can reactivate the dormant UBE3A allele,
providing the first proof of concept of pharmacological re-
activation of paternal UBE3A as a potential therapeutic
intervention for AS [9]. Because of the anticancer activity
of Top1 inhibitors, many derivatives that overcome the
limitations of camptothecins [10, 41, 42] have been syn-
thesized for clinical development. One of these, topotecan,
is FDA-approved for ovarian and lung cancers [43], while
another, irinotecan, is approved for colon cancers [44].
However, these compounds may have limited clinical po-
tential for treating AS. For example, topotecan has severalflaws such as decreased bioavailability due to plasma pro-
tein binding of the lactone hydrolysis product, removal
from cells by drug efflux transporters, and long infusion
times necessitated by relatively low stability of the ternary
drug-DNA-enzyme cleavage complexes [10, 18]. These
limitations prompted us to search for novel Top1 inhibi-
tors as potential AS therapeutics, with the expectation
that lead candidates could then be vetted for having im-
proved CNS bioavailability and better safety profiles. For
these studies, we focused on indenoisoquinoline-derived
Top1 inhibitors that might overcome the limitations of
topotecan [10]. Of many indenoisoquinoline-derived Top1
inhibitors, indotecan and indimitecan were selected to
examine their unsilencing effects on paternal Ube3a
because of their similar ability to effectively inhibit almost
100% of Top1 enzymatic activity [33] and recent comple-
tion of phase I clinical trials (ClinicalTrials.gov ID:
NCT01051635).
Here, we demonstrate that indenoisoquinoline-derived
Top1 inhibitors are potent Ube3a unsilencers, with dif-
ferent unsilencing properties. Of the compounds we
tested in vitro, indotecan (LMP400) [10, 34] appears to
have more favorable paternal Ube3a unsilencing proper-
ties than topotecan. While both topotecan and indote-
can exhibit CNS penetrance [18, 40], there are not yet
data available to directly compare their relative CNS bio-
availability; there is a need to carefully establish the CNS
bioavailability of indotecan. One potential advantage of
indotecan is that it is not a substrate for the transporters
ABCG2 and MDR1 [32], suggesting that it may stay lon-
ger in the CNS than topotecan because transporters ex-
trude topotecan from the brain [19]. Moreover, although
the cytotoxicity profile of indotecan is similar to that of
topotecan, its efficacy and potency are better than
topotecan. Indimitecan (LMP776) [10] appears to be
more toxic than topotecan, while the three other inde-
noisoquinoline derivatives (indotecan, DB-IV-58, and
DB-V-37) showed similar cytotoxicity to topotecan in
our cultured cortical neurons. In addition, the efficacy of
indimitecan is lower than that of topotecan. The struc-
tural differences in indenoisoquinoline-derived com-
pounds are responsible for their different unsilencing
effects. The only structural difference between indotecan
and indimitecan is in the side chain which is appended
to the heterocyclic system that intercalates in the DNA
break generated by Top1 [10, 23]. These characteristics
will be important considerations for the future design of
paternal UBE3A unsilencers. Although indotecan ex-
hibits better efficacy and potency than topotecan, the
similar cytotoxicity of the two drugs must be considered
for in vivo applications. Importantly, the DNA cleavage
complex patterns of indotecan are different from topote-
can in a manner that may confer some important
advantages for clinical use. Indenoisoquinolines such as
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camptothecins such as topotecan [45], which, based on
the mechanism of Ube3a unsilencing [26], should
enhance Ube3a unsilencing as we observed. Moreover,
after drug removal, the Top1-DNA complexes induced
by indenoisoquinolines persist under conditions where
camptothecin-induced Top1-DNA complexes com-
pletely reverse [45]. This observation further suggests
that the similar cytotoxicity of indotecan might be offset
by the potential for a briefer treatment regimen in vivo,
which remains to be addressed. Known off-target effects
for topoisomerase inhibitors generally lead to the transi-
ent downregulation of long genes [11, 46, 47]. Genome-
wide analyses are necessary to reveal all potential off-
target effects for indenoisoquinolines (e.g., indotecan).
Alternatively, an in silico analysis using SEA (similarity
ensemble approach; http://sea.bkslab.org) enables us to
predict off-targets. SEA analysis revealed that indotecan
possesses 55 potential off-targets, including aurora kin-
ase A, aurora kinase B, and acetylcholinesterase. Regard-
less of off-target effects, clinical trials have demonstrated
that, at least at the concentrations examined, indotecan
is well tolerated in a clinical population [34]. However,
it still remains to be addressed whether off-target ef-
fects arise at the concentration at which indotecan is
effective, as we reported that indotecan has a very low
EC50 of ~ 26 nM to produce Ube3a unsilencing.
We tested 11 structural analogues of indotecan/indimite-
can for their ability to unsilence paternal Ube3a, and these
compounds could be roughly categorized based on their
ability to inhibit Top1 in cell-free assays: those compounds
(DB-IV-26, DB-IV-50, DB-IV-56, DB-IV-58, DB-V-37, and
DB-V-41) that have 100% of the ability of camptothecin to
stabilize the ternary drug-DNA-Top1 cleavage complexes
[37, 48], those compounds (DB-V-46, DB-V-47, and
MNR-IV-64) that inhibit between 50 and 75% of Top1 [37],
and those compounds (MJ-II-66A) that inhibit between 20
and 50% of Top1 [30]. We also tested DB-III-17, as this is
an intermediate compound for synthesizing or modifying
the analogues. The compounds with lower Top1 inhibitory
activities (DB-III-17, DB-V-46, DB-V-47, and MJ-II-66A)
showed a very limited therapeutic index. Their ambiguous
EC50 values were mainly due to limited effective dose
ranges. Although we did not test their cytotoxicities in our
cultured cortical neurons, we expect that they are more
toxic than topotecan because we could not measure the
fluorescence intensity in unsilenced UBE3A-YFP protein,
possibly due to cell death produced at concentrations
> 1 μM. On the other hand, we observed similar efficacy
and potency of three compounds (DB-IV-50, DB-IV-56,
and MNR-IV-64) with between 75 and ~ 100% Top1
inhibitory activities relative to camptothecin, but their
effectiveness seems to be less than those of indotecan
or topotecan. Interestingly, although DB-IV-26 andDB-V-41 have ~ 100% Top1 inhibitory activity, their
EC50 values were also ambiguous due to limited effective
dose ranges. Since the cleavage complexes are critical for
producing paternal Ube3a unsilencing [26], we suspect
that their cleavage complexes may not be stable enough
to produce paternal Ube3a unsilencing. More importantly,
the various hydroxylated side chains contribute to differ-
ences in the pharmacological action in Ube3a unsilen-
cing. For example, the compounds with lower Top1
inhibitory activities (DB-III-17, DB-V-46, DB-V-47, and
MJ-II-66A) either lack the hydroxylated side chains that
potentially serve as hydrogen-bond acceptors/donors
that enable Top1 inhibitory activities and cytotoxicity
at physiological pH [49] or the hydroxylated side chain
is cyclic. On the other hand, other compounds posses-
sing dimethoxy or methylenedioxy groups, and/or
straight hydroxylated side chains, which appear to be
the main contributors to Top1 inhibitory activity and
cytotoxicity, effectively unsilence paternal Ube3a.
Taken together, our study suggests that clinical
development of paternal Ube3a unsilencers will re-
quire optimization of Top1 inhibition and cytotoxicity
through modulating chemical characteristics, including
the length of the side chains. Although in vivo assays
are necessary to further evaluate the unsilencing
effects of indenoisoquinolines, this study provides a
framework for developing novel AS therapies using
different classes of Top1 inhibitors.
Conclusions
Angelman syndrome is a neurodevelopmental disorder
without effective therapeutic interventions. However,
pharmacological restoration of the epigenetically silenced
copy of UBE3A could be one promising approach. Pharma-
cological inhibition of topoisomerase I (Top1) leads to
re-expression of the dormant UBE3A allele. Here, we
provided pharmacological profiles of indenoisoquinoline-
derived Top1 inhibitors as Ube3a unsilencers in mouse
neurons to identify potential AS clinical candidates. Our
data suggest that a number of indenoisoquinolines, and in
particular indotecan (LMP400), are potent unsilencers of
the paternal Ube3a allele and should be further assessed
in vivo for their translational potential.
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